Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to...
September 29, 2025 16:05 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage...
September 19, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions ...
September 08, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated...
August 28, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...
August 13, 2025 07:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term...
August 04, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...
July 18, 2025 09:25 ET | Source: ARS Pharmaceuticals, Inc.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights...
May 27, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...
May 14, 2025 07:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc....